BHM® IVD PRODUCTS RECEIVE CE MARKING

Birmingham Biotech has registered the BHM® COVID-19 Neutralising Antibody Rapid Test, a rapid test for the qualitative detection of neutralising antibodies to COVID-19 in whole blood, serum, or plasma. This product is used as an auxiliary evaluation of the presence of neutralising antibodies. Neutralising antibodies mainly bind to the RBD site of the virus to block viral infection.

Birmingham Biotech has registered the BHM® COVID-19 Antigen Rapid Test (Strip), for the qualitative detection of the nucleocapsid protein antigen from SARS CoV-2 from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19. The test employs a eco-friendly design by eliminating the plastic housing for the test strip.

Birmingham Biotech has registered the BHM® COVID-19 Antigen Rapid Test (Saliva), for the qualitative detection of the nucleocapsid protein antigen from SARS CoV-2 from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19. The test allows for saliva sampling which may be suitable for populations who find other methods of sampling intrusive.

Birmingham Biotech has registered the BHM® Pregnancy (HCG) Rapid Test, a lateral flow immunochromatographic assay for the qualitative detection of human chorionic gonadotropin (HCG) in urine or serum specimen.

Birmingham Biotech has registered the BHM® COVID-19 / INFLUENZA A / INFLUENZA B / RSV Antigen Rapid Test, a rapid, immunochromatographic assay for the qualitative detection of COVID-19 antigen, influenza type A (including the subtype H1N1) and B nucleoprotein antigen, Respiratory Syncytial Virus antigens in specimens.

Birmingham Biotech has registered the COVID-19/Influenza A/Influenza B Detection Kit, for the qualitative detection of COVID-19/Influenza A/Influenza B in swab samples. It provides an aid in the diagnosis of infection with the above viruses.

Birmingham Biotech has registered the BHM® Viral Transportation Medium, for the collection and transportation of clinical influenza, avian influenza, hand, foot and mouth disease, measles and other virus specimens, as well as chlamydia, mycoplasma and ureaplasma, COVID-19 etc. specimens.

Previous
Previous

Validation Results for BHM® COVID-19 Antigen Rapid Test Shows up to 98.34% Accuracy in Lab Testing

Next
Next

PARTNERSHIP WITH CHUNG MEI PHARMACEUTICAL FOR TAIWANESE PRODUCT DISTRIBUTION